Inspire Investing LLC Makes New Investment in Bioventus Inc. $BVS

Inspire Investing LLC bought a new position in Bioventus Inc. (NASDAQ:BVS) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 182,918 shares of the company’s stock, valued at approximately $1,670,000. Inspire Investing LLC owned approximately 0.22% of Bioventus at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in BVS. Marshall Wace LLP lifted its stake in Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after purchasing an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after purchasing an additional 1,887 shares during the period. Deutsche Bank AG raised its holdings in shares of Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after purchasing an additional 1,908 shares during the period. Finally, Engineers Gate Manager LP lifted its position in shares of Bioventus by 6.0% in the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after buying an additional 3,909 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Stock Down 3.5%

Bioventus stock opened at $9.44 on Wednesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. Bioventus Inc. has a one year low of $5.81 and a one year high of $11.25. The company has a 50-day simple moving average of $9.51 and a 200-day simple moving average of $8.78. The firm has a market capitalization of $788.62 million, a P/E ratio of 23.02, a P/E/G ratio of 1.26 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities analysts expect that Bioventus Inc. will post 0.77 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on BVS. Barrington Research reaffirmed an “outperform” rating and issued a $14.00 price target on shares of Bioventus in a report on Tuesday. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research note on Tuesday, June 16th. Craig Hallum upped their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Bioventus presently has an average rating of “Buy” and a consensus price target of $14.20.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.